Radiology core faculty ushers along liver cancer treatment / Dr. Matthew Scheidt

Matthew Scheidt MD

Matthew Scheidt MD

Not long after Matthew Scheidt, MD came to Peoria in late 2012, he saw an opportunity to provide patients with liver cancer in central Illinois with another option for treatment.

Called radioembolization, the minimally invasive procedure involves using a catheter positioned within the hepatic artery to deliver tiny beads which are used to block the blood supply to the tumor(s) and at the same time administer high dose radiation to liver tumors from the inside.

“It’s pretty high-tech and saves a lot of the healthy liver,” says Dr. Scheidt, Associate Program Director of the College of Medicine’s Vascular/Interventional Fellowship Program. He adds: “I just think it’s a good procedure to bring to patients in order to improve their quality of life and provide hope for this patient population.”

Dr. Scheidt is an Assistant Professor of Clinical Radiology and core faculty member of the fellowship, a program now in its 17th year. A member of the Central Illinois Radiological Associates, Dr. Scheidt sees and treats patients at OSF Saint Francis Medical Center.

Prior to coming to Peoria, Dr. Scheidt worked and trained at the Medical College of Wisconsin in Milwaukee, where he also completed a fellowship in vascular and interventional radiology. He completed his residency in diagnostic radiology at Indiana University.

Historically, liver cancer often is treated by systemic chemotherapy, surgery, or even liver transplant, but some people fall into categories where they cannot have surgery to remove the tumor because of its size or location, says Dr. Scheidt. In addition to providing a better quality of life, the targeted treatment option offers an opportunity to shrink tumors so that patients may ultimately become a candidate for surgery or transplant in the future.

Patients who undergo the one-time procedure can go home the same day, he said, contrasting standard chemotherapy regimens which are often 14 to 16 weeks long. The type of radiation material used in the targeted embolization procedure is active for only up to 11 days.

“It’s not a cure but it does provide people with an improved, more prolonged quality of life, and sometimes can help bridge the patient until surgery or transplant,” Dr. Scheidt said.


Article source: http://peoria.medicine.uic.edu/UserFiles/Servers/Server_442934/File/Peoria/Departments%20and%20Programs/Advancement/Pathways/UIC%20Pathways%20SUMMER%20FALL%202014%20SPREADS.pdf